Roswell Park Cancer Institute Purchases Six Ion Torrent Sequencers
CARLSBAD, Calif., Feb. 21, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced that the new Center for Personalized Medicine (CPM) at Roswell Park Cancer Institute (RPCI) has purchased four Ion Proton™ sequencers and two Ion Personal Genome Machine™ (PGM™) sequencers.
Founded in 1898, Roswell Park Cancer Institute was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and is a member of the prestigious National Comprehensive Cancer Network.
"A key part of our mission at the Center involves research into new therapies, new diagnostic tools and better ways of predicting patient outcomes," said Carl Morrison, MD, DVM, Executive Director of the Center for Personalized Medicine. "The sequencers will be central to this work, quickly generating vast amounts of genomic data that will help us to understand the mechanisms of how cancer develops and spreads."
"The combination of the Ion Proton™ sequencer and the Ion PGM™ sequencer will give the researchers from Roswell Park Cancer Institute a simple workflow from discovery to validation," said Life Technologies Chief Operating Officer Mark Stevenson. "Over 1,000 organizations have adopted Ion Torrent technology in the past two years, giving our company more than 60 percent of the desktop sequencer market and reflecting the huge demand for the speed, simplicity and affordability of Ion Torrent technology."
All products referenced are for research use only and not for use in diagnostic procedures.
About Life Technologies Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum, with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, Gibco®, Ambion®, Molecular Probes® and Novex®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.8 billion in 2012. Visit us at our website: http://www.lifetechnologies.com.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact